ConclusionCervical insufficiency is increasingly recognized as an inflammation-related syndrome. While novel biomarkers show promise for predicting outcomes, their clinical value must be further validated through large-scale, prospective, multicenter studies.
Wu et al. (Sun,) studied this question.